TGFBR1 and neoplasm: Crucially, ZD6474 treatment inhibited only the growth of organoids and mouse tumours with simultaneous activation of Wnt, MAPK, and TGFβ/ALK5 signalling (Supplementary Fig. 7f–h), exposing a potential therapeutic vulnerability of tumours harbouring increased growth-factor signalling via TGFβ/ALK5 activation.